TCIM
CLDX icon

TIAA CREF Investment Management’s Celldex Therapeutics CLDX Stock Holding History

TIAA CREF Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-28,093
Closed -$982K – 3086
2018
Q1 		$982K Sell
28,093
-15,342
-35% -$594K ﹤0.01% 2455
2017
Q4 		$1.85M Buy
43,435
+18,228
+72% +$781K ﹤0.01% 2182
2017
Q3 		$1.08M Buy
25,207
+4,241
+20% +$159K ﹤0.01% 2477
2017
Q2 		$777K Buy
20,966
+3,861
+23% +$171K ﹤0.01% 2667
2017
Q1 		$926K Sell
17,105
-1,436
-8% -$74.8K ﹤0.01% 2545
2016
Q4 		$985K Sell
18,541
-786
-4% -$44.7K ﹤0.01% 2545
2016
Q3 		$1.17M Sell
19,327
-7,446
-28% -$464K ﹤0.01% 2463
2016
Q2 		$1.76M Buy
26,773
+3,046
+13% +$193K ﹤0.01% 2203
2016
Q1 		$1.34M Sell
23,727
-652
-3% -$73.4K ﹤0.01% 2306
2015
Q4 		$5.73M Sell
24,379
-894
-4% -$195K ﹤0.01% 1472
2015
Q3 		$4M Sell
25,273
-758
-3% -$215K ﹤0.01% 1695
2015
Q2 		$9.85M Buy
26,031
+396
+2% +$157K 0.01% 1156
2015
Q1 		$10.7M Buy
25,635
+810
+3% +$290K 0.01% 1094
2014
Q4 		$6.8M Sell
24,825
-1,057
-4% -$263K ﹤0.01% 1404
2014
Q3 		$5.03M Sell
25,882
-787
-3% -$171K ﹤0.01% 1615
2014
Q2 		$6.53M Buy
26,669
+922
+4% +$208K ﹤0.01% 1478
2014
Q1 		$6.82M Sell
25,747
-389
-1% -$149K ﹤0.01% 1387
2013
Q4 		$9.49M Buy
26,136
+1,048
+4% +$404K 0.01% 1185
2013
Q3 		$13.3M Sell
25,088
-751
-3% -$258K 0.01% 930
2013
Q2 		$6.05M Buy
+25,839
New +$5.09M ﹤0.01% 1390

Other funds holding CLDX

KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TIAA CREF Investment Management's CLDX Position: Q2 2018 in Review

TIAA CREF Investment Management sold out of Celldex Therapeutics (CLDX) in Q2 2018, closing a stake of 28,093 shares — an estimated $982K sold.

TIAA CREF Investment Management first reported a position in CLDX in Q2 2013 and held it in 20 quarters. The position peaked at $13.3M in Q3 2013. 102 funds tracked by Wall St. Rank hold CLDX as of Q2 2018.

  • TIAA CREF Investment Management reported no remaining Celldex Therapeutics position as of Q2 2018 after selling out during the quarter.
  • TIAA CREF Investment Management sold 28,093 Celldex Therapeutics shares in Q2 2018, an estimated $982K.
  • TIAA CREF Investment Management first reported a position in Celldex Therapeutics in Q2 2013 and held it in 20 quarters.
  • TIAA CREF Investment Management's Celldex Therapeutics position peaked at $13.3M in Q3 2013.
  • 102 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2018.

Based on TIAA CREF Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.